Income Before Tax
Pre-Tax Income
Pfizer Pre-Tax Income decreased by 4.9% to $3.17B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 13.8%, from $2.79B to $3.17B. Over 2 years (FY 2021 to FY 2024), Pre-Tax Income shows a downward trend with a -42.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementIncome Statement
SectionIncome Before Tax
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026
How to read this metric
This provides a view of profitability that is not skewed by varying tax rates or one-time tax credits.
Detailed definition
A company's profits before the deduction of corporate income tax. It combines operating performance with non-operating f...
Peer comparison
Used to compare companies across different tax jurisdictions to see who generates more raw profit.
Metric ID:
is_income_before_taxHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.61B | $7.84B | $4.18B | $9.05B | $11.45B | $9.00B | $5.23B | $6.27B | $2.27B | -$3.35B | $3.42B | -$103.00M | $4.72B | $0.00 | $2.79B | $3.04B | $3.33B | $3.17B |
| QoQ Change | — | +18.6% | -46.6% | +116.4% | +26.5% | -21.4% | -41.9% | +19.9% | -63.8% | -247.7% | +202.1% | -103.0% | >999% | -100.0% | — | +9.3% | +9.5% | -4.9% |
| YoY Change | — | — | — | — | +73.2% | +14.9% | +25.1% | -30.7% | -80.2% | -137.2% | -45.4% | -104.5% | +240.7% | — | -18.6% | >999% | -29.3% | +13.8% |
Range-$3.35B – $11.45B
CAGR-15.9%
Avg YoY Growth+229.0%
Median YoY Growth-18.6%
Business Segments
| Segment | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Biopharma | $17.17B | $14.67B | $11.93B | $10.94B | $7.00B | $7.55B | $7.07B | $6.84B |
| Total | $11.45B | $9.00B | $5.23B | $6.27B | $2.27B | -$3.35B | $2.79B | $3.17B |
Pre-Tax Income at Other Companies
Frequently Asked Questions
- What is Pfizer's pre-tax income?
- Pfizer (PFE) reported pre-tax income of $3.17B in Q1 2026.
- How has Pfizer's pre-tax income changed year-over-year?
- Pfizer's pre-tax income increased by 13.8% year-over-year, from $2.79B to $3.17B.
- What is the long-term trend for Pfizer's pre-tax income?
- Over 2 years (2021 to 2024), Pfizer's pre-tax income has grown at a -42.5% compound annual growth rate (CAGR), from $24.31B to $8.03B.
- What does pre-tax income mean?
- The total profit a company made before paying its income taxes.